Home › Kanser sa Suso › Kansas

Pag-aaral pangklinika para sa Kanser sa Suso sa Kansas

26 pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa mga site sa Kansas.

Mga Lungsod sa Kansas

Opisyal na teksto ng pag-aaral (English)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Veteran Administration Eastern Kansas Healthcare, Leavenworth
at 4 pa

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

The University of Kansas Cancer Center, Westwood

Nagre-recruitPhase 3

Edad 60 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06377852

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Cancer Center of Kansas, Wichita

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT06492616

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

University of Kansas Hospital-Cancer Center, Fairway

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07287917

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

University of Kansas Cancer Center, Westwood
Cancer Center of Kansas, Wichita

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06982521

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
HaysMed, Hays
at 10 pa

Nagre-recruitPhase 3

Edad 18 hanggang 60 · Kababaihan · Na-update Set 2, 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

AMR Kansas City Oncology, Kansas City

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06072612

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

Hays Medical Center Dreiling-Schmidt Cancer Institute, Hays
KCCC West, Kansas City
KCCC Overland Park, Overland Park
at 3 pa

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Lahat ng edad · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT02302742

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

University of Kansas Cancer Center, Kansas City
University of Kansas Cancer Center-Overland Park, Overland Park

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06500481

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

University of Kansas Medical Center, Fairway

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06263543

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

University of Kansas Cancer Center, Kansas City

Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo

Edad 45 hanggang 74 · Kababaihan · Na-update Ago 4, 2026 · NCT06195306

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

University of Kansas Medical Center (KUMC), Westwood

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT05579366

E-Mindfulness Approaches for Living After Breast Cancer

Cotton O'Neil Cancer Center / Stormont Vail Health, Topeka

Nagre-recruitPhase 3

Edad 18 hanggang 50 · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT06748222

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

University of Kansas Cancer Center, Kansas City

Nagre-recruitPhase 2

Edad 18 hanggang 55 · Kababaihan · Na-update Hul 27, 2026 · NCT06184750

HER2-positive Breast Cancer Registry

The University of Kansas Cancer Center, Westwood

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 17, 2026 · NCT06603597

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

University of Kansas Cancer Center, Kansas City

Nagre-recruitPhase 2

Edad 35 pataas · Kababaihan · Na-update Hul 7, 2026 · NCT05941520

Integrated Cancer Repository for Cancer Research

Saint Luke's Cancer Instititute - South, Overland Park

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

The University of Kansas Cancer Center, Westwood

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update May 18, 2026 · NCT06757634

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

The University of Kansas Cancer Center (KUCC), Fairway
The University of Kansas Cancer Center - Westwood, Kansas City
KUCC - Indian Creek, Overland Park
at 3 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT07220135

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

University of Kansas Cancer Center, Kansas City
The University of Kansas Cancer Center - Olathe, Olathe
University of Kansas Cancer Center-Overland Park, Overland Park
at 8 pa

Nagre-recruitPhase 3

Edad 50 hanggang 70 · Lahat ng kasarian · Na-update Abr 23, 2026 · NCT04852887

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

The University of Kansas Cancer Center, Westwood

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 20, 2026 · NCT06374459

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

HaysMed, Hays
Lawrence Memorial Hospital, Lawrence
The University of Kansas Cancer Center - Olathe, Olathe
at 6 pa

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204

EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

University of Kansas Cancer Center, Westwood

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT06401421

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

Cancer Center of Kansas, Wichita

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2025 · NCT04553770

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

University of Kansas Medical Center, Kansas City

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo

Edad 30 hanggang 65 · Kababaihan · Na-update Okt 29, 2025 · NCT00291096

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

HaysMed University of Kansas Health System, Hays
University of Kansas Cancer Center-West, Kansas City
University of Kansas Cancer Center, Kansas City
at 5 pa

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 8, 2025 · NCT03418961

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.